


## NF-κB-IN-8


<b>Cat. No.:</b>	HY-149248
<b>CAS No.:</b>	2924565-59-1
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>21</sub> N <sub>3</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	399.44
<b>Target:</b>	NF-κB
<b>Pathway:</b>	NF-κB
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI) <sup>[1]</sup> .								
<b>In Vitro</b>	<p>NF-κB-IN-8 (Compound L26) (10 μM) inhibits ALP activity by 64.30%<sup>[1]</sup>.</p> <p>NF-κB-IN-8 (1-10 μM, 24 h) inhibits expression of IL-6 and TNF-α in RAW 264.7 cells<sup>[1]</sup>.</p> <p>NF-κB-IN-8 (0-50 μM) inhibits the binding of LPS to MD-2, determined by ELISA Assay<sup>[1]</sup>.</p> <p>NF-κB-IN-8 (50 μM, overnight) inhibits the formation of LPS/MD-2/TLR4 polymers in RAW264.7 cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>RAW264.7 cells</td> </tr> <tr> <td>Concentration:</td> <td>50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>Overnight</td> </tr> <tr> <td>Result:</td> <td>Inhibited the expression of LPS/MD-2/TLR4 polymers.</td> </tr> </table>	Cell Line:	RAW264.7 cells	Concentration:	50 μM	Incubation Time:	Overnight	Result:	Inhibited the expression of LPS/MD-2/TLR4 polymers.
Cell Line:	RAW264.7 cells								
Concentration:	50 μM								
Incubation Time:	Overnight								
Result:	Inhibited the expression of LPS/MD-2/TLR4 polymers.								
<b>In Vivo</b>	<p>NF-κB-IN-8 (Compound L26) (5 mg/kg, intra-gastrically administration) attenuates LPS-induced ALI in mice<sup>[1]</sup>.</p> <p>NF-κB-IN-8 (1000 and 1500 mg/kg, intra-gastrically administration) is low in toxic and safe in mice<sup>[1]</sup>.</p> <p>NF-κB-IN-8 (10 mg/kg, rats) shows T<sub>1/2</sub>: 4.2 h, C<sub>max</sub>: 163.288 μg/L<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>ALI mice induced by LPS<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intra-gastrically administration</td> </tr> <tr> <td>Result:</td> <td>Downregulated the expression of pro-inflammatory factor Mrna (TNF-α). Decreased ALP level in bronchoalveolar lavage fluid. Inhibited the phosphorylation of p65 and increased the release of IκB-α. (WB assay, lung)</td> </tr> </table>	Animal Model:	ALI mice induced by LPS <sup>[1]</sup>	Dosage:	5 mg/kg	Administration:	Intra-gastrically administration	Result:	Downregulated the expression of pro-inflammatory factor Mrna (TNF-α). Decreased ALP level in bronchoalveolar lavage fluid. Inhibited the phosphorylation of p65 and increased the release of IκB-α. (WB assay, lung)
Animal Model:	ALI mice induced by LPS <sup>[1]</sup>								
Dosage:	5 mg/kg								
Administration:	Intra-gastrically administration								
Result:	Downregulated the expression of pro-inflammatory factor Mrna (TNF-α). Decreased ALP level in bronchoalveolar lavage fluid. Inhibited the phosphorylation of p65 and increased the release of IκB-α. (WB assay, lung)								

---



---

tissue sample)

---

## REFERENCES

---

[1]. Li X, et al. Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2. Eur J Med Chem. 2023 Apr 5;252:115289.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA